Skip to main content
. 2020 Feb 19;8(5):594–606. doi: 10.1177/2050640620905183

Figure 4.

Figure 4.

Reproducibility and power of the assay. (A) Schematic representation of PDO163 and PDO163W/R-free isolation and propagation using pancreatic ductal organoid media respectively supplemented17 or not with WNT3A/RSPOI8. (B) Survival analysis of a viability assay conducted on PDO163 and PDO163W/R-free. (C) Schematic representation of the comparison of multiple independent experiments vs. single experiment of drug screening. Cell death ratio (CDR) analysis of multiple viability assays (n = 5) vs. a single experiment conducted on (D) PDO163 (n = 5) and (E) PDO185 (n = 3). Drug response prediction using CDR is provided below each bar graph. Yes and No indicate respectively a positive drug response and a lack of drug response. PDO is considered to be sensitive when CDR of one of treatment conditions >1.30. GEM (gemcitabine); IRI (irinotecan); PAC (paclitaxel); RES., resistant; SENS., sensitive.